At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Pre-Market Trading 12-24 08:48:40 EST
4.03
-0.20
-4.73%
盘前4.08
+0.05+1.24%
08:44 EST
High4.29
Low4.01
Vol602.62K
Open4.21
D1 Closing4.23
Amplitude6.62%
Mkt Cap146.04M
Tradable Cap90.49M
Total Shares36.24M
T/O2.45M
T/O Rate2.68%
Tradable Shares22.46M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Biomea Fusion Advances Diabetes Treatment with Positive Study Results
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22Nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.